Mirum Pharmaceuticals’ Livmarli secures FDA nod to treat cholestatic pruritus
Mirum Pharmaceuticals has secured approval from the US Food and Drug Administration (FDA) for Livmarli (maralixibat) oral solution to treat cholestatic pruritus. Livmarli is an oral, once-daily inhibitor